BAQSIMI® (glucagon nasal powder)
Severe Hypoglycemia
MarketedCommercial Growth
Key Facts
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals' mission is to develop, manufacture, and market essential, high-barrier-to-entry pharmaceuticals, with a strategic focus on complex generics, proprietary products, and biosimilars. The company has achieved significant recognition, including an FDA Drug Shortage Assistance Award for its subsidiary, and commercial success with market-leading products like BAQSIMI® nasal glucagon. Its strategy leverages a fully integrated operational model, combining proprietary technology platforms in drug delivery with a diversified portfolio targeting endocrinology, pulmonology, and nephrology to drive sustainable growth.
View full company profileTherapeutic Areas
Other Severe Hypoglycemia Drugs
| Drug | Company | Phase |
|---|---|---|
| Gvoke VialDx Commercial Launch | American Regent | Approved |
| Zegalogue (dasiglucagon) | Zealand Pharma | Marketed |
| Gvoke® (glucagon) | Xeris Pharmaceuticals | Marketed |